The tweet was deleted by the author.
But we saved everything 🙂.
Edgewise Therapeutics announced the outcome of an End-of-Phase 2 meeting with the FDA for its EDG-7500 program in symptomatic hypertrophic cardiomyopathy. Separately, the stock edges lower on the day, trading at $37.53.
Edgewise Therapeutics announced a productive End-of-Phase 2 meeting with the FDA for EDG-7500 in symptomatic hypertrophic cardiomyopathy. The company stated the upcoming Phase 3 protocol will feature tolerability-based dose escalation without requiring safety echo monitoring. The announcement was posted directly by the company.
View post on X Loading...
The intraday range in the latest session widened sharply, fluctuating between $37.44 and $40, well above the typical weekly average. Shares of Edgewise Therapeutics are trading below the MA-20 and MA-50 levels, but remain above the MA-200, pointing to a mixed daily trend. The weekly low at $36.81 serves as the nearest support. RSI at 39.7 is approaching oversold territory, suggesting the recent decline could be getting stretched.
To determine whether the potential regulatory impact is being priced in, traders should watch for a close above $38.61 or a drop below $36.81. During the latest session, Edgewise Therapeutics stock saw trading swing between $37.44 and $40, marking an unusually wide session compared to previous weeks. While the past week featured a sharp move lower without a sustained trend, downside probability stands at 74% and upside at 26% for the coming trading week, with an expected range of $35.51 to $39.54. A close above $38.61 would suggest buyers are regaining control, while a fall below $36.81 would indicate sellers are reasserting themselves. On the weekly chart the longer-term picture stays constructive.
Previously it was reported that Edgewise Therapeutics’ technical setup had shifted to a more cautious short-term stance, with longer-term prospects remaining constructive. With the company now advancing EDG-7500 to Phase 3 and shares maintaining a mixed trend above the 200-day moving average, traders should closely monitor whether the stock can hold above the $36.81 support level in the sessions ahead.